Research – Trovagene (TROV) – Update on data readout

Posted on April 2, 2019 by Admin

Tuesday, April 2, 2019

Trovagene Inc. (TROV)

Improved and updated data from AML patients.

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

AACR Data
Presentation. The company presented data from a Phase 1b clinical trial of
onvansertib in patients with acute myeloid leukemia (AML) at the American
Association for Cancer Research (AACR) annual meeting on April 1st, 2019. The
anti-leukemic activity improved with an increased number of patients treated.
The disease control rate (DCR) rose to 89% (17/19 patients) from previous
reported rate of 83% (10/12 patients) at The American Society of
Hematology (ASH) on December 2018.
Digging Through Data. In addition to the improved DCR, the overall response
rate also increased; one patient with complete response (CR), one
incomplete blood recovery (iCR), one morphologic leukemia-freestate (MLFS) and
one partial response (PR) compar…

Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.

Research – Trovagene (TROV) – Updated prostate cancer data

Posted on April 2, 2019 by Admin

Wednesday, April 3, 2019

Trovagene Inc. (TROV)

Updated early prostate cancer data demonstrates sustained PSA levels.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

AACR
Presentation. The company had the second presentation from a Phase 2 study
of onvansertib in combination with Zytiga/prednisone in patients with metastatic
castration-resistant prostate cancer (mCRPC), at the American Association for
Cancer Research (AACR) annual meeting today, following the update from the
acute myeloid leukemia (AML) trial (refer to the note published on April 2nd,
2019).
Data Update in
Prostate Cancer. Onvansertib in combination with Zytiga/prednisone treatment
achieved a reduction of prostate specific antigen (PSA) levels in 2 out of
6 mCRPC patients. The previous data reported at
the Genitourinary Cancers Symposium (ASCO-GU, on February) showed
reduced PSA levels, however levels were relapsed. The company plans to
comm…

Get full report on Channelchek desktop.

FEATURE: Research | Podcast Series | Future of Copper

Posted on April 1, 2019May 4, 2022 by Admin

Sierra Metals (SMTS) What will drive expansion in 2019? More

Albany International Corp. (AIN) New CFO appointment: What does it signal? More

The NEW podcast series, from top-trending iTunes host, Brant Pinvidic, features celebrity CEOs of iconic brands you know and love, to the emerging growth companies and entrepreneurs you should be talking about. The most innovative Ideas, the inspirational People behind them, and the wealth of Opportunities they create… that’s IPO from Channelchek. More

Salem’s radio station sell-off
reduces debt. “Michael Kupinski, director of research at Noble Capital Markets,
Inc. in Boca Raton, Fla., believes the soft first quarter guidance should not
be a trend for the company…” More

Trovagene, Inc. (TROV), a clinical-stage oncology therapeutics company news: Phase 1b/2 dose escalation trial of Onvansertib in Relapsed/Refractory AML demonstrates safety, tolerability and relative durability with complete responses at highest dose levels. More

Endeavour Silver (EXK), a mid-tier precious metals mining company that owns and operates four high-grade, underground, silver-gold mines in Mexico, achieves commercial production at El Compas mine… More

Energy Fuels (UUUU), a leading US-based uranium mining company, supplying U₃O₈ to major nuclear utilities, provides an update on Vanadium production. More

Betting on The Future of Copper. The case for Dr. Copper: new sources of demand are positive for copper. Demand for copper is poised to benefit from greater usage for electric vehicles, communications and clean energy systems, such as solar thermal plants… More

Research – TherapeuticsMD (TXMD) — Assumption of Coverage

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

TherapeuticsMD (TXMD)

.

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD’s drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

…

Get full report on Channelchek desktop.

Research – Sierra Metals (SMTS) – 2018 full year recap

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

Sierra Metals (SMTS)

What will drive expansion in 2019?

Sierra Metals Inc is a precious and base metals producer in Latin America. The company acquires, explores, extracts, and produces mineral concentrates consisting of silver, copper, lead, zinc and gold in Mexico and Peru. Its activity includes the operation of the Yauricocha Mine in Peru, and the Bolivar and Cusi mines in Mexico.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Full year earnings modestly lower than expected. Sierra Metals reported a fourth quarter loss of
($0.01) per share and full year earnings of $0.12 per share, compared to our
respective per share estimates of $0.02 and $0.15. The variance to our
estimates was largely attributed to higher fourth quarter expenses, including
taxes. Fourth quarter and full year EBITDA were $15.3 million and $89.8
million.
Near-term expansions on the horizon. Production capacity at Yauricocha is expected to
increase from 3,150 tonnes per day to 3,600 tonnes per day in 2020, while
capacity at Bolivar is expected to increase from 3,600 tonnes per day to 4,200
tonnes per day by the fourth quarter of 2019. Capacity at Cusi is
expected to increase fro…

Get full report on Channelchek desktop.

Research – Albany International (AIN) – Appoints new CFO

Posted on April 1, 2019 by Admin

Monday, April 1, 2019

Albany International Corp. (AIN)

New CFO appointment: What does it signal?

Albany International
Corp. is a textiles and materials processing company. The Company operates
through two segments: Machine Clothing (MC) and Albany Engineered Composites
(AEC). Its MC segment supplies permeable and impermeable belts used in the
manufacture of paper, paperboard, nonwovens, fiber cement and various other
industrial applications.

Christian Herbosa, Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Management
Update. After market close last Friday, AIN announced the that
its Board of Directors appointed Stephen Nolan as CFO and Treasurer, effective
today. Mr. Nolan succeeds John Cozzolino, who had served as CFO and
Treasurer since 2011.
New CFO
Background. Prior to joining AIN, Mr. Nolan served as CFO at
Esterline, where he facilitated its sale to TransDigm. He also served as CFO
for Vista Outdoor, which he helped spin-off from Alliant Techsystems (ATK). He
also worked on the merger of ATK and Orbital Sciences to create Orbital ATK.
Before those positions, Mr. Nol…

Get full report on Channelchek desktop.

Research – Pyxis Tankers (PXS) – 2018 financial update

Posted on March 29, 2019 by Admin

Friday, March 29, 2019

Pyxis Tankers (PXS)

When Will The Refined Product Tanker Market Recover?

Pyxis Tankers Inc is a US-based international maritime transportation company which focuses on the product tanker sector. It owns a fleet which comprises of six double hull product tankers, which are employed under a mix of short- and medium-term time charters and spot charters.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Another tough
quarter due to rate weakness. Adjusted 4Q2018 EBITDA of $0.2 million was below $1.0 million
in 4Q2017 due to weaker MR tanker rates. Record low MR rates early in 4Q2018
caused a shortfall in TCE revenue (-$0.94 million) and more than offset positive
variances in opex ($0.15 million) and G&A expenses ($0.30 million).
Adjusting 2019
Estimate to reflect new contracts and 2H2019 recovery. Our 2019 EBITDA estimate moves to $6.9 million (from
$7.9 mill…

Get full report on Channelchek desktop.

Research – Dyadic (DYAI) – 2018 full year update

Posted on March 28, 2019 by Admin

Thursday, March 28, 2019

Dyadic International (DYAI)

Could 2019 be transformational?

Dyadic International Inc. is a biotechnology company developing a proprietary expression platform to manufacture of biologic products. The company is employing C1 technology, part of a fungi expression system, to produce variety of modalities of biologic products, including vaccines, oncolytic viruses, monoclonal and bispecific antibodies, as well as biosimilars.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

R&D
Advancement. The company continues to make progression in
establishing C1 expression production and the purification process in multiple
projects. The Schmallenberg virus (SBV) as part of the ZAPI project exceeded
the intended expression levels (17x), and is potentially the first to enter in
human trials. We believe glycan engineering intended in 2019 could be
transformational for the company.
Corporate
Updates. The proof of concept collaborations totaled nine projects,
including two newly added agreements with large pharmaceuticals in Q1 2019.
Dyadic continues to validate C1’s potential in biologic manufacturing, guiding
an $8-$10 million burn rate this year. However, business development efforts
are ongo…

Get full report on Channelchek desktop.

Podcast Launch: The Science of Investing in Biotechs

Posted on March 28, 2019 by Admin

First Episode: The science of investing in biotechs

In the inaugural episode, Brant Pinvidic (host of the iTunes top-trending Hollywood podcast “Why I’m Not…”) tries to navigate the minefield of challenges that biotech investors face. In his engaging everyman approach, Brant looks at the importance of getting a third-party, independent opinion, how to determine what’s real and unreal about patent protection and intellectual property, and probes into where you might find the next breakthrough in medicine. He’s not alone on this challenge. Joined by four of the members of the Noble Scientific Advisory Board – the who’s who of life sciences – together they show you how a detailed and disciplined approach, in this risk-reward-rich field, is the true science behind investing in biotechs.

Who should listen? Anyone who wants to invest in life science companies but may be afraid; EVERY CEO and CFO of a biotech company, as this elite group will be sure to provide some eye-openers; investment professionals who can help advise their clients in what to look for… and what to avoid when trying to sift through the hundreds and hundreds of life sciences companies, and find that gem to invest in, and; anyone interested in a lively debate among some of the world’s greatest minds in medicine…

The most innovative Ideas, the inspirational People behind them, and the wealth of Opportunities they create… that’s IPO from Channelchek.

watch the IPO series trailer

A Video Introduction to Enochian Biosciences

Posted on March 28, 2019 by Admin

Enochian Biosciences Inc. is a biopharmaceutical levering its gene therapy platform to treat patients with HIV/AIDS. The company has a diverse pipeline at the preclinical and discovery stage to treat and prevent infectious disease and cancer. In the infectious disease front, there are two key products i) the lead candidate, genetically modified cell therapy ENO-1001, that is currently at preclinical stage for treatment of patients with HIV/AIDS and ii) ENO-2001, a vaccine, to prevent HIV infection. In the oncology front, Enochian is developing agents ENO-1002, ENO-3001, and ENO-5001 to treat patients with relapse metastatic colon cancer. The company has established research and development agreements with Scripps Research Institute to conduct pre-new drug application (pre-IND) work to advance ENO-1001 in the clinic, and with University of California Los Angles (UCLA) to advance HIV program. Enochian BioSciences is headquartered in Los Angeles, California.

Link to Enochian page on Channelchek

Official Trailer: NEW Podcast Series- Icons of Business, Leaders of Emerging Companies

Posted on March 26, 2019 by Admin

CLICK HERE TO WATCH THE TRAILER

Upcoming episodes – first episode this Thursday

Kathy Ireland: From Supermodel, to socks, to mega-success (and a few failures along the way).

Christie Hefner: The best person for the job… running Playboy Enterprises for almost as long as Hef himself!

Artificial Intelligence: Could a person who is born 10 years from now, live to 120? Billionaires are banking on it.

The science of Investing in Biotechs: A world-class scientific advisory board (SAB) helps you steer through this formidable minefield.

David Weild IV: How the father of the JOBS ACT sees the future for emerging growth companies.

Research – 1-800-Flowers.com (FLWS) – Investor Day Highlights

Posted on March 25, 2019 by Admin

Monday, March 25, 2019

1-800-Flowers.com, Inc (FLWS)

Not resting on its florals.

1-800 Flowers.com Inc
is a United-States-based provider of gourmet food & gift baskets, consumer
floral, and BloomNet wire service. Gourmet food & gift baskets and consumer
floral jointly account for the majority of the company’s total revenue. The
company provides a broad range of merchandise, including fresh flowers,
premium, fruits, popcorn, specialty treats, cookies and baked gifts, premium
chocolates, confectionery, gift baskets, premium English muffins, steaks and
chops, and others.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Investor day reinforces strategy. The company held an Investor Day on March 22nd with detailed
presentations from key management personnel from consumer floral and the
gourmet food brands. The overall theme, highlighted across each of the business
segments, were centered around investments in new customer acquisition,
technological innovations, and increase cross-brand marketing efforts.
Holiday revenues strong. The Company provided color on the recent February 2019
Valentine’s Day holiday period, which displayed continued efforts to gain
market share. As this holiday time period is primarily heavy in floral
revenues, bot…

Get full report on Channelchek desktop.

Research – Prize Mining (PRZ:CA) – Initiation of Research Coverage

Posted on March 25, 2019 by Admin

Monday, March 25, 2019

Prize Mining (PRZ:CA)

Building a Future on Copper.

Prize Mining Corp is a Canada based resource exploration company. It is primarily engaged in the business activity of acquiring and exploring resource properties in Canada. All the operations of the company are carried out in Canada. The organization is focused on Kena and Daylight Gold project which is located in the Nelson area of British Columbia, Canada.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

Prize is largely a play
on expanding global demand for copper. While the Kena gold project is under strategic review,
the Manto Negro project is where management is positioning itself to focus the
greatest resources going forward in order to capitalize on expected growth in
copper demand.
Phase II drilling program
at Manto Negro. Management’s key objective at both projects has been
to consolidate contiguous land packages to form district-scale projects and to
build resources and reserves. Phase I and II drilling programs have been
completed at the Kena project and a Phase I drilling program has been completed
at Manto Negro. A Phase II program will entail drilling another 3,000 to
5,000 meters in 2019 follow…

Get full report on Channelchek desktop.